Severe Aplastic Anemia Clinical Trial
Official title:
A Research on Haploidentical Transplantation in Severe Aplastic Anemia Using Reduced-intensity Fludarabine-based Conditioning
This is a prospective case-control study on SAA patients treated with HSCT, order to further discuss and assess the safety, feasibility and effectiveness of HFD-HSCT which performed with reduced-intensity fludarabine-based conditioning regimen.Our findings would indicate that SAA patients who lack MSD benefited most if HFD-HSCT was performed with reduced-intensity fludarabine-based conditioning regimen, and our improved outcomes with HFD-HSCT may lead to a salvaged therapy and an expanded direct role for SAA in the future.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02828592 -
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
|
Phase 2 | |
Completed |
NCT02833805 -
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
|
Phase 2 | |
Terminated |
NCT01319851 -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT00004143 -
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
|
Phase 2 | |
Recruiting |
NCT05012111 -
Natural History of Acquired and Inherited Bone Marrow Failure Syndromes
|
||
Recruiting |
NCT03836690 -
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT06039436 -
Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired SAA Receiving sUCBT
|
||
Enrolling by invitation |
NCT05049668 -
RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial
|
||
Recruiting |
NCT01472055 -
Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT01351545 -
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
|
||
Completed |
NCT01703169 -
Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
|
Phase 2 | |
Withdrawn |
NCT01129323 -
Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia
|
N/A | |
Completed |
NCT00516152 -
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
|
Phase 2 | |
Recruiting |
NCT06069180 -
The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA
|
Phase 4 | |
Recruiting |
NCT03579875 -
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
|
Phase 2 | |
Recruiting |
NCT05720234 -
Avatrombopag Combined With IST as First-line Treatment for SAA
|
Phase 2 | |
Recruiting |
NCT04304820 -
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
|
Phase 2 | |
Terminated |
NCT00358657 -
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders
|
Phase 2 | |
Completed |
NCT02998645 -
Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia
|
Phase 2 | |
Active, not recruiting |
NCT03825744 -
Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
|
Phase 3 |